本文来自方正证券研究所《巨子生物(02367)公司点评报告:胶原棒势能超预期,可丽金线上高增拉动环比加速,关注新品迭代&医美获批增量》,欲了解报告详情,请阅读报告原文。分析师:周昕 S1220524100007;谷寒婷 S1220524030001点评内容事件:巨子生物披露2024年业绩,整体超市场预期24全年:收入55.39亿元/+57.2%,归母净利20.62亿元/+42.1%;24H2:收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.